This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovations of Mitchell Henry Keylor
Introduction
Mitchell Henry Keylor is an accomplished inventor based in Malden, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases involved in various diseases.
Latest Patents
Keylor holds a patent for "Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." This invention focuses on certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives that act as potent inhibitors of LRRK2 kinase. These compounds may be beneficial in treating or preventing diseases associated with LRRK2 kinase, such as Parkinson's Disease. The patent also covers pharmaceutical compositions that include these compounds and their applications in medical treatments.
Career Highlights
Keylor is currently associated with Merck Sharp & Dohme Corporation, where he continues to innovate in the pharmaceutical sector. His work is pivotal in advancing treatments for diseases that significantly impact public health.
Collaborations
Keylor has collaborated with notable colleagues, including David Annunziato Candito and Thomas H Graham. These partnerships enhance the research and development efforts within his field.
Conclusion
Mitchell Henry Keylor's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through targeted therapies. His work in developing LRRK2 inhibitors is a testament to the potential of scientific research in addressing complex medical challenges.